Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025

Company Highlights - Alnylam Pharmaceuticals had an active 2024, with a significant highlight being the positive results from the Phase III HELIOS-B study of Amvuttra (vutrisiran) in ATTR amyloidosis with cardiomyopathy (ATTR-CM) [1] Clinical Trial Results - The Phase III HELIOS-B study of Amvuttra (vutrisiran) showed very positive results in treating ATTR-CM, a key development for the company [1] Future Prospects - The potential impact of the HELIOS-B study results on the company's future remains to be seen, but it represents a significant milestone in its clinical pipeline [1]